Rissing J P, Buxton T B, Harris R W, Shockley R K, Craven P, Moore W L
J Lab Clin Med. 1983 Sep;102(3):392-9.
Human intra-abdominal infections frequently yield Bacteroides fragilis and require specific antimicrobial and surgical therapy. Noninvasive immunologic assessment of this organism might allow more optimum therapy. Therefore we raised antisera in goats to Bacteroides fragilis ATCC 23745 and allowed it to react with a solid-phase capsular polysaccharide-protein antigen extracted from the same organism. Preliminary work disclosed that 10 ng/ml antigen could be detected in competition assays in both saline and dialyzed rat urine. Results were manifest by diminution of bound antiglobulin alkaline phosphatase conjugate in an antigen-mediated antibody-inhibition enzyme-linked immunosorbent assay. Rats were then infected intra-abdominally with (1) B. fragilis ATCC 23745; (2) one of eight recent clinical isolates of B. fragilis; or (3) one of nine isolates representative of Enterobacteriaceae. Seventy-two rat urine samples obtained prior to infection disclosed essentially no assay inhibition: 98.3% +/- 10.3 (1 S.D.). Mean values of reagent antibody activity after incubation with urine aliquots from 24 hr samples collected between 24 and 72 hr were (1) strain 23745 (n = 35) 70.9% +/- 2.6 (S.E.); (2) eight isolates of B. fragilis (n = 49) 86.8% +/- 1.9; (3) nine isolates of Enterobacteriaceae (n = 47) 100.9% +/- 1.0; and (4) shams (n = 29) 95.5% +/- 1.55. Ascribing values less than or equal to 77.7% (2 S.D.) as positive, seven of the eight clinical B. fragilis isolates causing infection were detected in at least one 24 hr urine sample (sensitivity = 87% by organism); 12 of 17 infected rats were correctly identified as positive by at least one urine (sensitivity = 70.6% by rat). Specificity, as assessed in the Enterobacteriaceae group, was 89% (by organism) and 94.5% (by rat). Collectively, these results suggest the presence of a potentially specific, soluble antigen excreted in the urine of rats with B. fragilis infection.
人类腹腔内感染常分离出脆弱拟杆菌,需要特定的抗菌和手术治疗。对这种细菌进行非侵入性免疫评估可能有助于实现更优化的治疗。因此,我们用脆弱拟杆菌ATCC 23745免疫山羊制备抗血清,并使其与从同一细菌中提取的固相荚膜多糖 - 蛋白抗原发生反应。初步研究表明,在生理盐水和透析后的大鼠尿液的竞争试验中,均可检测到10 ng/ml的抗原。在抗原介导的抗体抑制酶联免疫吸附试验中,结合的抗球蛋白碱性磷酸酶偶联物减少表明了试验结果。然后,大鼠经腹腔感染:(1)脆弱拟杆菌ATCC 23745;(2)最近分离的8株脆弱拟杆菌临床菌株之一;或(3)代表肠杆菌科的9株菌株之一。感染前采集的72份大鼠尿液样本基本未检测到试验抑制:98.3%±10.3(1个标准差)。与感染后24至72小时采集的24小时尿液等分试样孵育后,试剂抗体活性的平均值为:(1)23745菌株(n = 35)70.9%±2.6(标准误);(2)8株脆弱拟杆菌(n = 49)86.8%±1.9;(3)9株肠杆菌科菌株(n = 47)100.9%±1.0;(4)假手术组(n = 29)95.5%±1.55。将小于或等于77.7%(2个标准差)的值判定为阳性,8株引起感染的脆弱拟杆菌临床菌株中有7株在至少一份24小时尿液样本中被检测到(按菌株计算敏感性 = 87%);17只感染大鼠中有12只至少有一份尿液被正确鉴定为阳性(按大鼠计算敏感性 = 70.6%)。在肠杆菌科组中评估的特异性为89%(按菌株计算)和94.5%(按大鼠计算)。总体而言,这些结果表明,感染脆弱拟杆菌的大鼠尿液中存在一种潜在的特异性可溶性抗原。